Twist Bioscience (TWST) Q2 2026: Therapeutics Revenue Surges 55% on AI-Driven Demand Expansion
AI-driven drug discovery and robust NGS demand propelled Twist Bioscience to its 13th straight quarter of sequential revenue growth, with therapeutics revenue up sharply as the platform’s breadth and scale advantage expands. Margin discipline and targeted automation investments reinforce the company’s trajectory toward profitability in Q4, even as academic and industrial segments lag. Management’s confidence is underpinned by broad-based growth and a clear path to sustained operating leverage.
Summary
- AI-Enabled Discovery Drives Therapeutics Outperformance: Twist’s platform is powering a step-change in drug discovery volume and value as AI adoption accelerates.
- NGS Segment Returns to Double-Digit Growth: Oncology diagnostics and MRD applications are fueling a durable rebound in sequencing tools demand.
- Profitability Target Remains Intact: Margin expansion and disciplined OPEX management support a credible path to adjusted EBITDA breakeven in Q4.
Performance Analysis
Twist Bioscience delivered 19% year-over-year revenue growth in Q2, extending its streak of sequential gains to 13 quarters. This performance was anchored by a 28% surge in DNA synthesis and protein solutions, with therapeutics revenue up 55%—outpacing the broader life science tools market and reflecting robust adoption among pharma and biotech customers. Notably, the company’s AI-enabled drug discovery work is materially increasing both the number and complexity of sequences ordered, expanding deal sizes and driving higher-value service adoption.
NGS (Next-Generation Sequencing), which comprises the largest revenue segment, grew 12% year-over-year and 9% sequentially, led by oncology diagnostics and a ramp in minimal residual disease (MRD) testing applications. Gross margin expanded by 200 basis points to 51.6%, with incremental margin gains moderated by deliberate investments in capacity and digital infrastructure. Operating expenses rose with commercial and automation investments, but management signaled a $6 million sequential OPEX improvement in Q4 through targeted workforce reductions and ongoing cost initiatives.
- Therapeutics Outperformance: Large pharma and AI-driven biotech programs drove the majority of the 55% therapeutics revenue growth, now nearly $41 million quarterly.
- Geographic Breadth: EMEA and APAC regions posted 22% and 30% growth respectively, while China remains a minimal contributor (1% of revenue).
- Gross Margin Expansion: Margin improved to 51.6%, supported by scale and process improvements, though sequential gains were tempered by upfront investment in new product lines and capacity.
Academic and industrial segments remain challenged by funding and cyclical headwinds, but Twist is capturing share through pricing actions and product breadth. Cash burn was contained, with $171.7 million in liquidity at quarter-end, and the company resolved a major litigation overhang, clearing management focus for execution.
Executive Commentary
"Twist Core Technology Advantage is a semiconductor-based DNA synthesis platform that provides a structural advantage in cost, scale, and speed that feeds into every product and service we offer... We have delivered sustained revenue growth, expanded gross margin above 50%, invested strategically to drive continued return on that investment, and we remain firmly on track to achieve HSBC beta break-even in the first quarter of fiscal 2026."
Dr. Emily Leproust, CEO & Co-founder
"Gross margin expanded to 51.6 percent versus the prior year, an improvement of approximately 200 basis points. And we remain firmly on track for adjusted EBITDA breakeven in Q4... We are managing these investments with discipline. In April, we reduced 36 positions to reallocate resources to our highest return opportunity."
Adam Loponis, Chief Financial Officer
Strategic Positioning
1. Platform Scale and Breadth
Twist’s semiconductor-based DNA synthesis platform enables high-throughput, low-cost parallel production of customized DNA and proteins, providing a defensible edge in both scale and speed. The company’s ability to accept and manufacture up to 99% of customer sequence requests—soon to reach 99.9%—is a key driver of share gains, as customers increasingly seek a single provider for complex, end-to-end workflows.
2. AI-Driven Drug Discovery Acceleration
AI adoption is fundamentally expanding the market for synthetic DNA and protein solutions. Twist’s partnerships with Amazon Web Services and leading research institutions validate its leading role in enabling AI-powered antibody design. As AI models proliferate, the volume and complexity of orders increases, allowing Twist to upsell downstream services such as protein expression and data characterization.
3. NGS Reacceleration and Oncology Focus
NGS tools returned to double-digit growth, with oncology diagnostics and MRD testing (minimal residual disease, a method for detecting cancer recurrence) representing high-value, recurring revenue streams. Twist’s customizable enrichment panels and rapid turnaround are well-aligned with the technical demands of these applications, supporting both clinical and commercial adoption.
4. Margin Expansion and Operating Leverage
Margin improvement is driven by process automation and disciplined investment, particularly in backend workflows tailored to new product “flavors.” The company continues to automate not just production, but also the automation processes themselves, increasing capacity within existing facilities and supporting scalable growth without commensurate cost increases.
5. Diversification and Resilience
Despite funding pressures in academic and industrial segments, Twist’s broad portfolio and pricing strategies are enabling market share gains. The company’s ability to serve diverse customers—from pharma to diagnostics to academia—provides resilience against cyclical or sector-specific slowdowns.
Key Considerations
Twist’s Q2 showcased the compounding impact of platform scale, AI-driven demand, and disciplined execution. The company’s strategic focus on end-to-end workflows, rapid product iteration, and customer-centric flexibility positions it to capture incremental share as synthetic biology and genomics markets evolve.
Key Considerations:
- AI Adoption as a Growth Catalyst: The proliferation of AI models in drug discovery is increasing both the number and complexity of DNA/protein orders, expanding Twist’s addressable market and upsell potential.
- NGS Segment Durability: Oncology and MRD applications are driving recurring, high-sensitivity panel demand, supporting stable, high-margin NGS growth.
- Margin Trajectory Linked to Automation: Ongoing investment in backend automation is expected to yield further gross margin gains as new product lines scale.
- Academic and Industrial Headwinds: Funding constraints persist, but Twist’s pricing actions and breadth are enabling share capture in shrinking segments.
- Litigation Resolution Removes Overhang: Settlement of the securities class action ($17.1 million) eliminates a major distraction, allowing management to focus fully on growth and profitability.
Risks
Academic and industrial funding pressures remain a drag on segment growth, and while AI-driven demand is robust, the pace of new customer onboarding and order volume remains sensitive to biotech funding cycles and pharma R&D budgets. Gross margin expansion depends on continued execution of automation initiatives and scaling new product lines. Competitive intensity from niche DNA providers and evolving customer requirements could pressure pricing or share if Twist’s acceptance rates and service breadth do not keep pace.
Forward Outlook
For Q3 2026, Twist guided to:
- Total revenue of $114 million to $115 million, representing approximately 19% year-over-year growth at the midpoint.
For full-year 2026, management raised guidance:
- Total revenue of $442 million to $447 million, up 17% to 19% year-over-year.
Management highlighted several factors that underpin their outlook:
- NGS is expected to drive sequential growth in the second half, with a return to 20% segment growth in Q4.
- Adjusted EBITDA breakeven remains forecast for Q4, supported by ongoing OPEX discipline and automation-driven margin expansion.
Takeaways
Twist’s platform scale and AI-aligned product strategy are powering above-market growth, with therapeutics and NGS both contributing to a resilient, diversified revenue base.
- AI-Driven Therapeutics Growth: The company’s ability to serve high-volume, complex orders for AI-enabled drug discovery is unlocking larger deal sizes and new customer segments, driving outsized growth in therapeutics.
- Margin and Cash Discipline: Investments in automation and targeted workforce reductions are supporting margin expansion and a credible path to profitability, even as OPEX rises to fund growth initiatives.
- Future Watchpoint: Investors should monitor the pace of NGS adoption in clinical diagnostics, continued AI-driven order volume, and the company’s ability to maintain high sequence acceptance rates as complexity rises.
Conclusion
Twist Bioscience’s Q2 results highlight a business in compounding mode, with platform-driven scale, AI-enabled demand, and disciplined execution supporting robust growth and a clear path to profitability. The company’s multi-segment exposure and end-to-end workflow capability position it well for sustained share gains as synthetic biology and genomics adoption accelerate.
Industry Read-Through
Twist’s results signal a broader inflection in synthetic biology and genomics tools, with AI-driven drug discovery materially expanding the volume and complexity of DNA and protein synthesis orders across the industry. The rebound in NGS demand—particularly in oncology diagnostics and MRD—points to renewed growth for sequencing tools and consumables providers. Competitive differentiation is increasingly defined by platform breadth, automation, and the ability to serve diverse, end-to-end workflows. Providers unable to scale with rising complexity or meet rapid turnaround expectations risk ceding share to integrated, automation-driven players.